Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
TESARO, Inc. (TSRO) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/24/2019 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Triggering Events That Accelerate...
Docs: "Second Supplemental Indenture, by and between the Company and the Trustee",
"TESARO, Inc. Provides Notice of Fundamental Change, Conversion Rate Adjustment pursuant to Make-Whole Adjustment Event and Supplemental Indenture WALTHAM, Mass., Jan. 24, 2019 — TESARO, Inc. , an oncology-focused biopharmaceutical company, today announced that pursuant to the terms of the Indenture and the First Supplemental Indenture to the Indenture governing the terms of its 3.00% Convertible Senior Notes due 2021 , a Fundamental Change and a Make-Whole Adjustment Event, as such terms are defined in the Indenture, occurred as a result of completion of the offer and the merger , respectively, contemplated by the Agreement and Plan of Merger, dated December 3, 2018 , by and between TESARO, GlaxoSmithKline plc and Adriatic Acquisition Corporation. As a result of the Merger being a Make-Who..."
01/22/2019 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of TESARO, Inc",
"Amended and Restated Bylaws of TESARO, Inc"
12/04/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "TESARO, Inc. GIVES NOTICE OF ANTICIPATED MAKE-WHOLE ADJUSTMENT EVENT TO HOLDERS OF ITS CONVERTIBLE SENIOR NOTES"
12/03/2018 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, among the Company, GlaxoSmithKline plc and Adriatic Acquisition Corporation (pursuant to Item 601(b)(2) of Regulation S-K, the Company hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or exhibit to the Agreement and Plan of Merger)",
"Form of Tender and Support Agreement, between GlaxoSmithKline plc, Adriatic Acquisition Corporation and the stockholders of the Company party thereto"
11/01/2018 8-K Quarterly results
Docs: "TESARO ANNOUNCES THIRD-QUARTER 2018 OPERATING RESULTS · ZEJULA® Q3 net sales totaled $63 million compared to $39 million for Q3 2017 · Top-line results for PRIMA trial of ZEJULA monotherapy for first-line ovarian cancer patients regardless of BRCA mutation status anticipated in late 2019 · Data presented at ESMO for TSR-042 indicate robust activity in patients with MSI-high endometrial cancer; TSR-042 BLA submission planned for 2H 2019"
09/05/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "TESARO ANNOUNCES EXPANSION TO SECOND STAGE OF JASPER TRIAL OF ZEJULA® IN COMBINATION WITH TSR-042 IN NON-SMALL CELL LUNG CANCER · All evaluable patients experienced tumor shrinkage · Protocol defined response criteria achieved and trial expansion ongoing"
07/18/2018 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
Docs: "Pro Forma Financial Information Related to the Sale"
06/29/2018 8-K Other Events
06/29/2018 8-K Other Events
05/11/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment to the TESARO, Inc. 2012 Employee Stock Purchase Plan"
05/03/2018 8-K Quarterly results
Docs: "TESARO ANNOUNCES FIRST-QUARTER 2018 OPERATING RESULTS"
03/20/2018 8-K Regulation FD Disclosure
03/14/2018 8-K Regulation FD Disclosure
02/27/2018 8-K Quarterly results
Docs: "TESARO ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 OPERATING RESULTS"
02/02/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "TESARO TO ANNOUNCE FOURTH-QUARTER 2017 FINANCIAL RESULTS ON FEBRUARY 27, 2018 WALTHAM, MA - February 2, 2018 - TESARO, Inc. will announce fourth-quarter 2017 financial results on Tuesday, February 27, 2018, after the close of the U.S. financial markets. During the conference call and live audio webcast at 4:15 p.m. ET on February 27, 2018, TESARO's senior management team will discuss the Company's operating results in greater detail, as well as the status of its development programs and commercial products. For the month of December, ZEJULA® achieved approximately 60% market share in the U.S. among PARP inhibitors utilized in patients with ovarian cancer, according to IntrinsiQ. This market-leading share position in ovarian cancer is consistent with the share ZEJULA achieved in prior month..."
01/16/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "TESARO Announces Updates to the U.S. Prescribing Information for VARUBI® Injectable Emulsion"
01/08/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "TESARO, Inc. presentation to be used at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California beginning January 8, 2018"
12/06/2017 8-K Other Events
11/21/2017 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
11/13/2017 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/07/2017 8-K Quarterly results
Docs: "TESARO ANNOUNCES THIRD-QUARTER 2017 OPERATING RESULTS"
10/27/2017 8-K Quarterly results
09/18/2017 8-K Quarterly results
08/08/2017 8-K Quarterly results
Docs: "TESARO ANNOUNCES SECOND-QUARTER 2017 OPERATING RESULTS"
07/27/2017 8-K Form 8-K - Current report:
06/12/2017 8-K Form 8-K - Current report
06/05/2017 8-K Form 8-K - Current report
05/12/2017 8-K Form 8-K - Current report
05/10/2017 8-K Form 8-K - Current report
05/09/2017 8-K Form 8-K - Current report
03/31/2017 8-K Form 8-K - Current report
02/28/2017 8-K Form 8-K - Current report
01/12/2017 8-K Form 8-K - Current report
01/09/2017 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy